Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 4/20 | 0.75 |
| ▸ | PIK3C2G | O75747 | 4/20 | 0.75 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.75 |
| ▸ | AURKA | O14965 | 3/20 | 0.75 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.75 |
| ▸ | DCLK1 | O15075 | 2/20 | 0.75 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.75 |
| ▸ | TNK2 | Q07912 | 16/20 | 0.64 |
| ▸ | MAPK7 | Q13164 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20628279 | 0.90 | PIK3CD (0.74) | PIK3CDPIK3C2GPIK3CGAURKAAURKB | |
| SCHEMBL17465864 | 0.86 | PIK3CG (1.00) | PIK3CDPIK3C2GPIK3CGAURKAAURKB | |
| SCHEMBL20628558 | 0.81 | DCLK1 (0.73) | PIK3CDPIK3C2GPIK3CGAURKAAURKB | |
| SCHEMBL21938547 | 0.79 | PIK3CD (0.70) | PIK3CDPIK3C2GPIK3CGAURKAAURKB | |
| SCHEMBL20628428 | 0.78 | PIK3CG (0.81) | PIK3CDPIK3C2GPIK3CGAURKAAURKB | |
| SCHEMBL20628275 | 0.78 | PIK3CD (0.81) | PIK3CDPIK3C2GPIK3CGAURKAAURKB | |
| SCHEMBL19457412 | 0.78 | PIK3CD (1.00) | PIK3CDPIK3C2GPIK3CGAURKAAURKB | |
| SCHEMBL20628380 | 0.78 | TNK2 (0.75) | PIK3CDPIK3C2GPIK3CGLRRK2TNK2 | |
| SCHEMBL21938543 | 0.76 | PIK3CD (0.76) | PIK3CDPIK3C2GPIK3CGAURKAAURKB | |
| SCHEMBL16065860 | 0.75 | TNK2 (0.76) | PIK3CDPIK3C2GPIK3CGAURKAAURKB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220280530-A1 | PREVENTION OR TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | Anhui Newstar Pharmaceutical Development Co., Ltd. (CN) | 2022-09-08 | — | — | US | disclosed |
| US-10975092-B2 | Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof | ANHUI NEW STAR PHARMACEUTICAL DEVELOPMENT CO., LTD. (CN) | 2021-04-13 | — | — | US | disclosed |
| US-20200115386-A1 | PYRIMIDINE SEVEN-MEMBERED-RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | Anhui New Star Pharmaceutical Development Co., Ltd . (CN) | 2020-04-16 | — | — | US | disclosed |
| EP-3424929-A1 | PYRIMIDINE SEVEN-MEMBERED-RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | Anhui New Star Pharmaceutical Development Co., Ltd (CN) | 2019-01-09 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10975092-B2 | Pyrimidine seven-membered-ring compounds, preparation method therefor, pharmaceutical composition thereof, and uses thereof | MST1, STK11, MSTN | PIK3CD 309/4885PIK3C2G 1027/4885PIK3CG 551/4885 |
| US-20200115386-A1 | PYRIMIDINE SEVEN-MEMBERED-RING COMPOUNDS, PREPARATION METHOD THEREFOR, PHARMACEUTICAL COMPOSITION THEREOF, AND USES THEREOF | MST1, STK11, MSTN | PIK3CD 309/4885PIK3C2G 1027/4885PIK3CG 551/4885 |
| US-20220280530-A1 | PREVENTION OR TREATMENT OF DISEASES AND DISORDERS ASSOCIATED WITH TISSUE DAMAGE | MST1, MSTN, MST1R | PIK3CD 2015/4885PIK3C2G 3871/4885PIK3CG 2586/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.